What is Dey's Medical Stores (Manufacturing) Ltd?

Dey's Medical Stores (Manufacturing) Ltd is one of India's oldest pharmaceutical manufacturers, incorporated in 1957 in Kolkata, West Bengal. The company manufactures prescription and OTC pharmaceutical products and has strong brand equity in Eastern India. It is associated with Cipla Limited, one of India's leading pharmaceutical companies.

What is the relationship between Dey's Medical and Cipla?

Dey's Medical Stores became part of Cipla Limited's portfolio through acquisition. Cipla, headquartered in Mumbai, is one of India's top three pharmaceutical companies. The association has provided Dey's Medical access to Cipla's manufacturing standards, R&D capabilities, and broader distribution network.

What products does Dey's Medical manufacture?

Dey's Medical manufactures a range of pharmaceutical products including OTC consumer healthcare products, prescription formulations, and respiratory medicines. The 'Dey's Lung Care' franchise including respiratory treatments has been a well-known product line. The company is known for cough syrups, antiseptics, and related pharmaceutical products popular in Eastern India.

Is Dey's Medical listed on Indian stock exchanges?

No, Dey's Medical Stores (Manufacturing) Ltd is not listed on BSE or NSE. It is an unlisted public limited company, and its shares are available in the unlisted market at approximately ₹400 per share.

When was Dey's Medical incorporated?

Dey's Medical Stores (Manufacturing) Ltd was incorporated in 1957 in West Bengal, making it one of India's oldest active pharmaceutical manufacturers with over 65 years of operating history.

What is the significance of the Dey's brand in pharmaceuticals?

The 'Dey's' brand is a well-recognized pharmaceutical name in Eastern India, particularly in West Bengal. The brand is associated with consumer healthcare and respiratory medicine products. The Dey's Lung Care range has been part of India's respiratory pharmaceutical landscape for decades.

How do I buy Dey's Medical Stores unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for Dey's Medical Stores?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell Dey's Medical Stores shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

Dey's Medical Stores Unlisted Share Price | Buy Dey's Medical Stores Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

Dey's Medical Stores Unlisted Share Price | Buy Dey's Medical Stores Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

Dey's Medical Stores (Manufacturing) Ltd is one of India's oldest pharmaceutical manufacturers, incorporated in Kolkata in 1957 and now part of Cipla Limited's portfolio. With over 65 years of operating history and strong brand recognition in Eastern India, the company occupies an established position in India's pharmaceutical landscape. The Dey's brand in consumer healthcare and respiratory medicine (Dey's Lung Care) has enduring recognition. Cipla's parentage provides manufacturing quality backing and distribution reach. India's growing pharmaceutical market, rising health awareness, and underpenetrated Eastern India market provide multi-year tailwinds. Investors in the unlisted market view Dey's Medical as a legacy brand asset with Cipla backing, available at ₹400 per share in the unlisted space.

Pros

Dey's Medical Stores is one of India's oldest pharmaceutical manufacturers, incorporated in 1957 in Kolkata — over 65 years of industry presence providing unmatched institutional knowledge and brand equity
Strong legacy brand recognition in Eastern India, particularly in West Bengal, where 'Dey's' is a household name in pharmaceuticals
Established product portfolio spanning over-the-counter (OTC) consumer healthcare products, prescription pharmaceuticals, and specialty formulations with decades of market acceptance
Cipla connection — Dey's Medical became part of Cipla Limited's portfolio, one of India's top pharmaceutical companies, providing access to Cipla's R&D, manufacturing standards, and distribution network
Kolkata headquarters provides access to Eastern India's large and growing pharmaceutical market — a region with historically lower penetration by large pharma multinationals
Dey's Lung Care brand (Asthalin and related products) has been a widely recognized franchise in respiratory medicine in India
As a listed subsidiary under a large pharmaceutical group, the company benefits from parent-level manufacturing quality, compliance, and supply chain infrastructure

Cons

Unlisted status and limited publicly available financial disclosures make it difficult for investors to assess standalone financial performance
As part of the Cipla ecosystem, Dey's Medical operates as a subsidiary with strategic direction determined at the Cipla parent level rather than independently
Indian pharmaceutical industry faces increasing regulatory scrutiny from USFDA, WHO, and CDSCO, requiring continuous compliance investment
Intense competition in OTC consumer healthcare from HUL (Lever Ayush), Dabur, Emami, and large pharma companies in the Eastern India market
Drug price controls under India's National Pharmaceutical Pricing Authority (NPPA) and the DPCO (Drug Prices Control Order) can cap revenue growth for controlled formulations
Eastern India pharmaceutical market, while large, has traditionally lower income levels and price sensitivity compared to Western and Northern India markets

Business Segments

Prescription Pharmaceuticals

Manufacture and sale of prescription-only formulations across therapeutic categories including respiratory, anti-infective, and gastrointestinal categories

OTC Consumer Healthcare

Over-the-counter products including cough preparations, antiseptics, topical formulations, and consumer healthcare products distributed through retail pharmacy networks

Respiratory Medicine (Dey's Lung Care)

Specialty respiratory products including bronchodilators, anti-asthmatic preparations, and related respiratory healthcare formulations

Revenue Model

Dey's Medical Stores generates revenue through manufacturing and sale of pharmaceutical formulations across prescription (Rx) and over-the-counter (OTC) segments. Revenue is driven by doctor prescriptions for Rx products, retail pharmacy pull-through for OTC products, and institutional sales to hospitals and government health programs. As part of Cipla's network, the company may also supply formulations to Cipla's distribution channels for Eastern India. Revenue is constrained by NPPA drug price controls on scheduled formulations but benefits from uncontrolled pricing on non-scheduled OTC products.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds14

Growth Plans

India's pharmaceutical market structural growth driven by rising income levels and health awareness

Eastern India's pharmaceutical market historically underpenetrated vs national average — significant growth headroom

Ageing Indian population increasing demand for chronic disease and respiratory medications

Cipla's strong brand and distribution network amplifying Dey's reach beyond Eastern India

Recent Developments

Cipla group integration and compliance upgrades

As part of Cipla's portfolio, Dey's Medical has benefited from the parent company's investment in manufacturing quality, pharmacovigilance systems, and regulatory compliance across its manufacturing sites, aligning with WHO-GMP and Indian CDSCO standards.

2022–2024

Eastern India pharma market growth

India's growing middle class in Eastern states including West Bengal, Odisha, and Jharkhand has expanded pharmaceutical consumption, providing structural growth opportunities for established regional pharma brands like Dey's Medical.

2023–2024

Comparable Companies

CompanyTypeTickerMkt Cap

Cipla LimitedListedCIPLA~₹1,10,000 Cr

Emami LimitedListedEMAMILTD~₹25,000 Cr

Dabur India LimitedListedDABUR~₹85,000 Cr

Torrent Pharmaceuticals LimitedListedTORNTPHARM~₹95,000 Cr

Frequently Asked Questions

About Dey's Medical Stores

Dey's Medical Stores (Manufacturing) Ltd is one of Kolkata's oldest and most respected pharmaceutical manufacturers, incorporated on 1 August 1957 with roots tracing back to the early twentieth century. The company manufactures a wide range of pharmaceutical preparations for human and veterinary use, including ophthalmic preparations, antibiotics, gastrointestinal medications, antidiabetic drugs, and herbal formulations. The Dey's brand has deep roots in Bengal's pharmaceutical heritage. The group includes a related retail entity — Dey's Medical Stores Private Ltd — which historically operated one of Kolkata's most prominent medical stores. Together, the Dey's group represents a multi-generational pharmaceutical enterprise deeply embedded in Eastern India's healthcare ecosystem. Dey's Medical Stores (Manufacturing) Ltd reported revenues of approximately ₹132 crore in FY2024, operating as a standalone manufacturing entity. The related retail/distribution entity reportedly generates revenues around ₹256 crore, reflecting the Dey's group's combined scale of ₹388 crore across its pharmaceutical manufacturing and distribution operations. The company's product range spans several therapeutic categories — ophthalmic drops and ointments (a specialty area), antibiotic preparations, antacids and gastro preparations, antidiabetic medicines, and an increasingly important herbal/Ayurvedic segment. Manufacturing facilities in Kolkata comply with Schedule M GMP requirements under the Drugs and Cosmetics Act. As an unlisted manufacturing entity, Dey's Medical is accessible only via secondary markets. The company competes in the branded generic pharmaceutical space, where Kolkata-based companies including Albert David, Nicholas Piramal (formerly Bengalee), and Indoco Remedies represent the competitive landscape.

Key Milestones

1957 — Dey's Medical Stores (Manufacturing) Ltd incorporated in West Bengal under CIN U24232WB1957PLC023528 by the Dey family

Common questions about unlisted shares

How do I buy Dey's Medical Stores unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Risk factors & red flagsInvestment risks and items flagged from public filings10

Fraud / GovernanceLow

India's DPCO (Drug Price Control Order) administered by NPPA places price ceilings on a wide range of essential medicines. Any expansion of price-controlled categories can cap revenue growth for Dey's Medical's formulations.

Source: Company Financial Filings

Regulatory / LegalLow

Indian pharmaceutical manufacturers face increasing regulatory scrutiny from CDSCO, WHO, USFDA, and MHRA. Manufacturing quality lapses can result in product recalls, import alerts, and reputational damage.

Source: Regulatory Filings

Operational RiskLow

The Indian OTC and consumer healthcare market is highly competitive with Dabur, Emami, Himalaya, HUL, and large pharma companies all competing in segments overlapping with Dey's products.

Source: AlphaHub Research

Fraud / GovernanceLow

As a Cipla subsidiary, Dey's Medical's strategic investments, R&D pipeline, and product launches are determined at the Cipla parent level, limiting independent strategic flexibility.

Source: Media Reports / Public Records

Fraud / GovernanceLow

India's pharmaceutical market is intensely competitive with generic manufacturers competing on price across all therapeutic categories, compressing margins for established branded generics.

Source: Company Financial Filings

Drug Price Control Risk

Regulatory Compliance Risk

Competition Risk

The Indian OTC and consumer healthcare market is highly competitive with Dabur, Emami, Himalaya, HUL, and large pharma companies all competing in segments overlapping with Dey's products.

Parent Dependency Risk

As a Cipla subsidiary, Dey's Medical's strategic investments, R&D pipeline, and product launches are determined at the Cipla parent level, limiting independent strategic flexibility.

Generic Competition Risk

India's pharmaceutical market is intensely competitive with generic manufacturers competing on price across all therapeutic categories, compressing margins for established branded generics.

Dey's Medical Stores (Manufacturing) Ltd

How settlement works

Get price alerts for Dey's Medical Stores (Manufacturing) Ltd

Discuss Dey's Medical Stores

Similar companies

Other ways to invest